TCR Gene Therapy in Pancreatic Cancer | NEJM
5 vistas
• 07/13/23
0
0
Empotrar
administrator
Suscriptores
Pancreatic cancer is resistant to most forms of therapy but may be vulnerable to T cells that recognize a “hot-spot” mutation — KRAS G12D — commonly found in that cancer. New research findings are summarized in a short video.
To see the full article, follow this link: https://nej.md/3wS9STm
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios